Levodopa microparticles for pulmonary delivery: photodegradation kinetics and LC stability-indicating method

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Analytical Chemistry

Background:

• Oral levodopa is the standard Parkinson's disease treatment but has poor pharmacokinetics and diminishing efficacy.
• Pulmonary drug delivery offers a promising alternative to overcome oral levodopa limitations.
• Chitosan, hyaluronic acid, and HPMC are polymers investigated for novel pulmonary formulations.

Purpose of the Study:

• To develop a stability-indicating liquid chromatography method for quantifying levodopa microparticles.
• To determine the photodegradation kinetics of levodopa in solution.
• To analyze a novel pulmonary levodopa formulation and support stability studies.

Main Methods:

• Development and validation of a stability-indicating liquid chromatography method.
• Photodegradation kinetic studies of levodopa in solution.
• Quantitative analysis of levodopa microparticles in a novel pulmonary formulation.

Main Results:

• A validated analytical method was successfully established for levodopa microparticle quantification.
• Photodegradation kinetics of levodopa in solution were determined.
• The method was applied to analyze the novel pulmonary formulation and stability study samples.

Conclusions:

• A robust analytical method enables the characterization of levodopa microparticles for pulmonary delivery.
• Understanding levodopa photodegradation is crucial for formulation stability and efficacy.
• This approach supports the development of improved pulmonary levodopa formulations for Parkinson's disease.